Stock Traders Purchase High Volume of Put Options on Poseida Therapeutics (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 5,174 put options on the company. This is an increase of approximately 3,372% compared to the average daily volume of 149 put options.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of Poseida Therapeutics during the 3rd quarter worth about $37,000. Barclays PLC raised its holdings in Poseida Therapeutics by 132.7% in the 3rd quarter. Barclays PLC now owns 120,464 shares of the company’s stock valued at $345,000 after acquiring an additional 68,688 shares during the period. XTX Topco Ltd lifted its position in Poseida Therapeutics by 47.1% during the third quarter. XTX Topco Ltd now owns 182,888 shares of the company’s stock worth $523,000 after acquiring an additional 58,587 shares during the last quarter. State Street Corp boosted its holdings in shares of Poseida Therapeutics by 2.3% during the third quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after acquiring an additional 38,770 shares during the period. Finally, Fred Alger Management LLC acquired a new position in shares of Poseida Therapeutics in the third quarter valued at approximately $369,000. 46.87% of the stock is currently owned by institutional investors.

Poseida Therapeutics Stock Performance

Shares of PSTX traded up $6.52 during midday trading on Tuesday, reaching $9.38. The stock had a trading volume of 21,172,146 shares, compared to its average volume of 643,383. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a 50 day simple moving average of $2.78 and a 200-day simple moving average of $2.92. The firm has a market cap of $914.17 million, a PE ratio of -4.54 and a beta of 0.54. Poseida Therapeutics has a one year low of $1.87 and a one year high of $9.38.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.